- Home
- Heart Failure
Heart Failure
Hypertrophic Cardiomyopathy in Review: ESC–HFA 2022 & How to Differentiate HCM From Its Phenocopies
- 0.50 AMA PRA Credit
Published:
Learning objectives
- Recall the efficacy and safety of existing HCM treatments and summarise results from ongoing trials with experimental treatments
- Differentiate the signs and symptoms of HCM from other conditions that frequently mask, or mimic the disease and in the presence of comorbidities
Making Gains in HFpEF: An Appraisal of Where We Are Now
Published:
Learning objectives
- Identify HFpEF patients who may benefit from being initiated on an SGLT-2 inhibitor
- Recall current inertia rates amongst prescribers who manage heart failure
- Adopt effective treatment strategies for HFpEF patients early in the disease course
- Recall current guideline directed medical therapy options in HFpEF
- Review clinical, real world and quality of life evidence for the use of SGLT-2 inhibitors in HFpEF
Hypertrophic Cardiomyopathy in Review: Highlights of ACC 2022
- 0.25 AMA PRA Credit
Published:
Learning objectives
- Recall the efficacy and safety of existing HCM treatments and summarise results from ongoing trials with experimental treatments
Heart Failure Management in a Changing Paradigm
- 1 EBAC
Published:
Learning objectives
- Recall the utility of EF in heart failure treatment, patient selection and treatment response
- Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
- InIncorporate quality of life measures for assessing therapeutic efficacy in HF
- Recall outcomes from heart failure trials from recent congress and publications and their impact on practice
The 2022 ACC Heart Failure Guidelines: What Do They Mean for Your Practice?
Published:
Learning objectives
- Summarise the main updates to the 2022 ACC heart failure (HF) guidelines
- Compare updates from the ACC with the 2021 ESC HF guidelines
- Recall guideline recommendations for the initiation of foundational therapy for heart failure
- Adopt foundational GMDT early in the disease course
- Postulate how ejection fraction will be used in future trials and in future guidelines
- Review existing and forthcoming trial evidence on SGLT-2 inhibitors in HFpEF
Hypertrophic Cardiomyopathy: Application of Emerging Data and Genetic Testing in Clinical Practice
- 0.75 AMA PRA Credit
Published:
Learning objectives
- Recall the efficacy and safety of existing HCM treatments
- Summarise results from ongoing trials with experimental treatments
- Stratify individuals with HCM signs and symptoms for subsequent investigation and/or genetic screening